We have demonstrated a significant increase in activity in immunocompetent GBM models, enhancement of immunostimulatory response with increased secretion of damage-associated molecular patterns such as HMBG1 and calreticulin, and synergy with immune checkpoint inhibitors40. Here, CALR is linked to glioblastoma.